Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

46.320
+0.2600.56%
Volume:2.07M
Turnover:95.63M
Market Cap:307.43B
PE:33.65
High:46.500
Open:46.380
Low:45.920
Close:46.060
52wk High:94.869
52wk Low:45.660
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.26
T/O Rate:0.80%
Dividend:0.23
Dividend Rate:0.50%
EPS(LYR):1.376
ROE:12.46%
ROA:7.02%
PB:4.09
PE(LYR):33.65
PS:8.41

Loading ...

AH Share Premium and Deviation Rankings as of June 1st

Stock News
·
Jun 01

HENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year

Deep News
·
May 29

AH Share Premium and Deviation Rankings as of May 29 Close

Stock News
·
May 29

Movement Alert|Hengrui Medicine Rises 3.01% in Regular Trading, Class 1 Innovative Drug Luzunore Sodium Tablets Approved for Market

Market Focus
·
May 29

HENGRUI PHARMA's Novel Drug SHR4640 Tablets Receive Marketing Authorization

Stock News
·
May 28

Jiangsu Hengrui Pharmaceuticals - Received Nmpa Notice Approving Class 1 Innovative Drug Ruzinurad Tablets (Shr4640 Tablets) for Marketing

THOMSON REUTERS
·
May 28

HENGRUI PHARMA's Subsidiary Receives Clinical Trial Approval for SHR-1819 Injection

Stock News
·
May 28

Movement Alert|Hengrui Medicine Falls 3.08% in Regular Trading, COINS Act Biotech Expansion Threat Continues to Pressure Stock

Market Focus
·
May 28

AH Premium and Deviation Rankings as of May 27th

Stock News
·
May 27

Pharmaceutical Sector Shows Resilience at Low Levels, Huabao Pharma ETF (562050) Rises Against Market Trend in Afternoon Session! Leading Stock Hengrui Pharma Surges 4%, Traditional Chinese Medicine Leaders All in the Green

Deep News
·
May 27

HENGRUI PHARMA Subsidiary Receives NMPA Approval for HRS-1635 Tablets Clinical Trial

Stock News
·
May 26

AH Premium and Deviation Rankings as of May 25th

Stock News
·
May 25

AH Share Premium Rankings for May 22nd

Stock News
·
May 22

Movement Alert|Hengrui Medicine Rises 3.44% in Regular Trading, Stabilizing Rebound After Post-BMS Cooperation Pullback

Market Focus
·
May 21

AH Share Premium and Deviation Rankings as of May 20th Closing

Stock News
·
May 20

HENGRUI PHARMA's ω-3 Triglyceride (2%) MCT/LCT Fat Emulsion/Amino Acids (16)/Glucose (30%) Receives Drug Registration Approval

Stock News
·
May 19

Schroders PLC Increases Stake in Hengrui Pharma by 663,000 Shares

Stock News
·
May 18

HENGRUI PHARMA's Subsidiary Gains Approval for Clinical Trials of SHR-3079 Injection

Stock News
·
May 14

AH Premium and Deviation Rankings as of May 14th Close

Stock News
·
May 14

Morgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion

Stock News
·
May 13